3D Biology™ Technology
For Research Use Only. Not for use in diagnostic procedures.
Helping Your Research
3D Biology is the ability to analyze combinations of RNA and protein simultaneously in a single experiment, from a single sample.
At NanoString, we are pioneering 3D Biology to accelerate your research and maximize the amount of information that can be generated from a single sample. Based on NanoString’s digital barcode technology and designed for flexibility, NanoString’s 3D Biology™ Technology and the nCounter® Vantage 3D™ portfolio of assays, provides a deeper view of cancer and immune biology and can be mixed and matched to answer a wide variety of biological questions.
- Quantify both RNA and protein in a single assay to use less precious material and uncover novel insights
- Simplify your workflow by comparing gene and protein expression for up to 800 targets in a single view
- Eliminate the potential bias inherent in merging data from different platforms
NanoString protein analysis leverages antibodies that are barcoded with unique synthetic DNA oligonucleotides for detection of proteins of interest. The DNA oligonucleotide is recognized by a unique reporter probe that contains a fluorescent barcode. Following sample preparation, RNA and protein can all be detected on the nCounter® platform yielding counts of mRNA and protein abundance.
Our Vantage 3D Assays are powered by 3D Biology technology and provide solutions across an expanding range of research areas. For more information download our Vantage 3D Brochure.
3D Flow™ Analysis: Seamlessly integrate standard flow cytometry cell sorting with downstream nCounter analysis to interrogate up to 30 proteins and 770 immune-related RNA simultaneously. View details here.
PDX Profiling: Simple and comprehensive profiling to assure that your PDX models are of consistent high quality and that you gain a deeper understanding of the molecular determinants of therapeutic response. View details here.
In the Lab
DIALOGUE maps multicellular programs in tissue from single-cell or spatial transcriptomics data.
Deciphering the functional interactions of cells in tissues remains a major challenge. Here we describe DIALOGUE, a method to systematically uncover multicellular programs (MCPs)—combinations of coordinated cellular programs in different cell types that form higher-order functional units at the tissue level—from either spatial data or single-cell data obtained without spatial information.
Advances in mixed cell deconvolution enable quantification of cell types in spatial transcriptomic data.
Mapping cell types across a tissue is a central concern of spatial biology, but cell type abundance is difficult to extract from spatial gene expression data. We introduce SpatialDecon, an algorithm for quantifying cell populations defined by single cell sequencing within the regions of spatial gene expression studies.
Surrogate endpoints for early-stage breast cancer: a review of the state of the art, controversies, and future prospects.
Drug approval for early-stage breast cancer (EBC) has been historically granted in the context of registration trials based on adequate outcomes such as disease-free survival and overall survival. Improvements in long-term outcomes have made it more difficult to demonstrate the clinical benefit of a new cancer drug in large, randomized, comparative clinical trials.